Auxilium Pharmaceuticals Inc., the biotechnology company developing a drug to treat penis curvature and hand lumps, rose the most in three years in Nasdaq trading after Pfizer Inc. bought the rights for as much as $485 million. Auxilium, of Malvern, Pennsylvania, gained $4.11, or 18 percent, to $27 at 10:41 a.m. New York time in Nasdaq Stock Market composite trading. It jumped as much as 22 percent, the biggest intraday gain since July 2005. Auxilium said late yesterday New York-based Pfizer, the worldâs biggest drugmaker, would help develop the shot Xiaflex for 46 European and Asian countries. The medicine targets Peyronieâs disease, a curvature of the penis, and Dupuytrenâs contracture, a growth of hard tissue in the hand. Both conditions are caused by the buildup of collagen, or scar tissue. Xiaflex is a biotechnology drug made up of three types of enzymes that can break down collagen. In Peyronieâs disease, the buildup of collagen on the shaft of the penis reduces flexibility, causes pain and can interfere with sexual intercourse. It affects an estimated 1 percent to 3 percent of men, according to Weill Cornell Medical Center in New York. In Dupuytrenâs contracture, found in 3 percent to 6 percent of Caucasians, especially those of northern-European descent, collagen buildup in the palm can contract the fingers and impair use of the hand. Auxilium said it expects to file an application with the U.S. Food and Drug Administration early next year for the drugâs use in treating the hand condition. The medicine is in the second of three phases of testing usually required for FDA approval for the penis-curvature condition and another illness known as frozen shoulder syndrome.